Literature DB >> 8208904

Classical versus non-renal Wegener's granulomatosis.

R A Luqmani1, P A Bacon, M Beaman, D G Scott, P Emery, S J Lee, A J Howie, N Richards, J Michael, D Adu.   

Abstract

We investigated whether 'limited' or 'non-renal' Wegener's granulomatosis (WG) differs from classical or 'renal' WG. Renal WG is characterized by necrotizing granulomatosis of the upper and or lower respiratory tract, accompanied by systemic vasculitis and focal segmental necrotizing glomerulonephritis. This last feature is absent in non-renal WG. In a prospective follow-up study of all identified cases presenting to a single teaching hospital, we reviewed 22 patients with non-renal WG, and compared their presentation and outcome with that of 28 patients with renal WG. Clinical and laboratory assessment of disease activity, frequency of death, relapse and end-stage renal disease were assessed. The two groups differed in clinical presentation, laboratory features and outcome. The group with non-renal WG had less cutaneous and pulmonary disease; the haemoglobin, white cell count and platelet count tended to be normal. Residual mortality was confined to the renal group. However, the groups shared many features, particularly their requirement for immunosuppressive therapy, since WG causes major tissue destruction regardless of whether it is a localized or widespread process. At the immunopathological level, the two groups appear to be part of a single disease spectrum. Importantly, the non-renal WG group may change the pattern of their disease to involve the kidney. Long-term follow-up of such patients is therefore essential.

Entities:  

Mesh:

Year:  1994        PMID: 8208904

Source DB:  PubMed          Journal:  Q J Med        ISSN: 0033-5622


  14 in total

1.  An unusual case of Wegener's granulomatosis developing with glomerulonephritis as an initial manifestation.

Authors:  Toshiro Sugimoto; Keiji Issiki; Masahiro Aoyama; Hironori Sakurai; Naoko Deji; Masayoshi Sakaguchi; Takashi Uzu; Atsunori Kashiwagi
Journal:  Rheumatol Int       Date:  2006-12-08       Impact factor: 2.631

2.  Limited Wegener's granulomatosis--is it limited?

Authors:  Svetlana Lisitsin; Raymond Farah; Moshe Shay
Journal:  Clin Rheumatol       Date:  2007-03-31       Impact factor: 2.980

Review 3.  The clinical utility of ANCA positivity.

Authors:  J D Edgar
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

Review 4.  Pulmonary vasculitis: classification, clinical features, and management.

Authors:  A Ciaccia; M Ferrari; F M Facchini; G Caramori; L Fabbri
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

Review 5.  Maintenance of clinical remission in ANCA-associated vasculitis.

Authors:  Raashid Luqmani
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

Review 6.  Pharmacological therapy for Wegener's granulomatosis.

Authors:  Eric S White; Joseph P Lynch
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 7.  Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.

Authors:  C Mukhtyar; R Luqmani
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

8.  Possible intrinsic association of anti-neutrophil cytoplasmic antibody-associated vasculitis coexisting with multiple myeloma.

Authors:  Huifang Liu; Jiachuan Xiong; Jun Zhang; Ying Zhang; Ling Nie; Yiqin Wang; Jinghong Zhao
Journal:  Oncol Lett       Date:  2016-07-13       Impact factor: 2.967

Review 9.  The pulmonary physician in critical care * illustrative case 3: pulmonary vasculitis.

Authors:  M Griffith; S Brett
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

10.  Interleukin-18 binding protein in the sera of patients with Wegener's granulomatosis.

Authors:  D Novick; D Elbirt; C A Dinarello; M Rubinstein; Z M Sthoeger
Journal:  J Clin Immunol       Date:  2008-07-02       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.